Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Institut de cancérologie Strasbourg Europe
With
UR 3072 - Mitochondries, Stress oxydant, Protection musculaire
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
For group 1 without trastuzumab :
Patients must be ≥ 18 years old
Patients with breast cancer stage I to III
Patients who will receive (neo)adjuvant anthracyclines and weekly taxane, without trastuzumab
Patients must have a social security coverage
Patients able to speak, read and understand French
For group 2 with trastuzumab :
Patients must be ≥ 18 years old
Patients with breast cancer grade I to III
Patients who will receive (neo)adjuvant anthracyclines and weekly taxane, with trastuzumab
Patients must have a social security coverage
Patients able to speak, read and understand French
You may not be if
History of cancer
Previous chemotherapy
Patients with known chronic pathology (musculoskeletal disorders, autoimmune, vascular or neuromuscular disease)
Pacemaker implantation
Contraindication to physical condition evaluation
Contraindication to local anesthesia required for microbiopsy
Patients \< 18 years old or patients ≥ 18 years old under guardianship, or supervision
Psychiatric, musculoskeletal or neurologic disorders
Women that are pregnant or breast-feeding
Clareo Health | Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer Patients
